• Tues news: Prostate cancer trials to watch. Merck’s subcutaneous Keytruda. Apellis sees positive in Astellas CRL. Future of Medicare price negotiations. JNJ psoriasis results. See more on our front page

Our Stock is Getting So Cheap, Benco or Burkhart Could Buy Us Now

anonymous

Guest
The company is certainly a take-over target with the stock price this low. A 50% Premium to yesterday’s closing price, still puts in just under $25.
Most stock holders would say “yes” to a price of $25 or thereabouts. A far cry from its height of $50.
 




This is what happens when you have poor leadership that broke a solid company, and then hired replacements (just a few, don't want to rock the boat too much) that either don't know what they are doing or aren't willing to burn down the rotting house and build it up again.
 




Burkhart isn't big enough to buy, they do only about $140-150mm/yearly sales, wouldn't know what to do with the crap stew in MN. Benco however has the muscle to do it but why? They're better off to let us fail and pick up the pieces when we go under.